Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04805788

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

Recurrent Hepatocellular Carcinoma Clinical Trial

Official title:
A Phase II Single Arm Trial of Stereotactic Body Proton Radiotherapy (SBPT) for Hepatocellular Carcinoma

Clinical Trial Summary

This phase II trial studies the effect of stereotactic body proton radiotherapy in treating patients with liver cancer. Proton radiotherapy is a type of treatment that uses high-energy beams to treat tumors.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the 3-month rate of patients experiencing an increase in Child-Pugh (CP) score by 2 or more points of 5-fraction stereotactic body proton radiotherapy (SBPT) in the treatment of hepatocellular carcinoma (HCC). SECONDARY OBJECTIVES: I. To determine the 3-month complication rate as defined by grade 3 or higher acute adverse event. II. To assess late toxicity with 2 year follow-up. III. To estimate the 6-month local control, liver disease control, progression free survival and overall survival. IV. To determine objective imaging response rates at 6 months by Modified (m) Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST criteria. V. To determine the value of volumetric imaging analysis compared to mRECIST and RECIST in the setting of HCC treated with stereotactic body radiotherapy (SBRT). CORRELATIVE AND EXPLORATORY OBJECTIVES: I. To evaluate patient-reported outcomes. II. To evaluate clinical features, treatment technique, and dose-volume parameters associated with better local control and fewer adverse events. III. To determine the value of additional imaging analyses and techniques for assessing tumor response after treatment with SBRT IV. To blood bank patient specimens for future analysis. OUTLINE: Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions. After completion of study treatment, patients are followed up at 2 weeks, 3 , 6, 12 and 24 months, then annually for 3 years. ;

Study Design

Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Recurrent Hepatocellular Carcinoma
  • Stage I Hepatocellular Carcinoma AJCC v8
  • Stage II Hepatocellular Carcinoma AJCC v8
  • Stage III Hepatocellular Carcinoma AJCC v8
Clinical Trial Details
NCT number NCT04805788
Study type Interventional
Source Mayo Clinic
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 24, 2021
Completion date February 15, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Completed NCT02728219 - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion N/A
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Active, not recruiting NCT04677088 - TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT03609268 - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma N/A
Completed NCT02613156 - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma N/A
Recruiting NCT02719782 - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation Phase 1
Recruiting NCT04800497 - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting NCT03257761 - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Phase 1
Terminated NCT02762266 - Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization Phase 3
Active, not recruiting NCT03655002 - IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Phase 1
Withdrawn NCT01318200 - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT01015833 - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 3
Recruiting NCT04663035 - Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Phase 2
Withdrawn NCT05327738 - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04615143 - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC Phase 2
Withdrawn NCT03634683 - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation Phase 1/Phase 2